Literature DB >> 19372765

Oxidative stress in Alzheimer disease.

Alejandro Gella1, Nuria Durany.   

Abstract

Alzheimer disease (AD) is a progressive dementia affecting a large proportion of the aging population. The histopathological changes in AD include neuronal cell death, formation of amyloid plaques and neurofibrillary tangles. There is also evidence that brain tissue in patients with AD is exposed to oxidative stress (e.g., protein oxidation, lipid oxidation, DNA oxidation and glycoxidation) during the course of the disease. Advanced glycation endproducts (AGEs) are present in amyloid plaques in AD, and its extracellular accumulation may be caused by an accelerated oxidation of glycated proteins. AGEs participate in neuronal death causing direct (chemical) and indirect (cellular) free radical production and consequently increase oxidative stress. The development of drugs for the treatment of AD that breaks the vicious cycles of oxidative stress and neurodegeneration offer new opportunities. These approaches include AGE-inhibitors, antioxidants and anti-inflammatory substances, which prevent free radical production.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19372765      PMCID: PMC2675154          DOI: 10.4161/cam.3.1.7402

Source DB:  PubMed          Journal:  Cell Adh Migr        ISSN: 1933-6918            Impact factor:   3.405


  96 in total

1.  Implication of altered redox regulation by antioxidant enzymes in the increased plasma pentosidine, an advanced glycation end product, in uremia.

Authors:  Y Ueda; T Miyata; T Hashimoto; H Yamada; Y Izuhara; H Sakai; K Kurokawa
Journal:  Biochem Biophys Res Commun       Date:  1998-04-28       Impact factor: 3.575

2.  Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine.

Authors:  M A Smith; L M Sayre; V E Anderson; P L Harris; M F Beal; N Kowall; G Perry
Journal:  J Histochem Cytochem       Date:  1998-06       Impact factor: 2.479

3.  Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease.

Authors:  W R Markesbery; M A Lovell
Journal:  Neurobiol Aging       Date:  1998 Jan-Feb       Impact factor: 4.673

4.  4-Hydroxynonenal, a product of lipid peroxidation, damages cholinergic neurons and impairs visuospatial memory in rats.

Authors:  A J Bruce-Keller; Y J Li; M A Lovell; P J Kraemer; D S Gary; R R Brown; W R Markesbery; M P Mattson
Journal:  J Neuropathol Exp Neurol       Date:  1998-03       Impact factor: 3.685

5.  Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis.

Authors:  S Hoyer
Journal:  J Neural Transm (Vienna)       Date:  1998       Impact factor: 3.575

6.  Increased nuclear DNA oxidation in the brain in Alzheimer's disease.

Authors:  S P Gabbita; M A Lovell; W R Markesbery
Journal:  J Neurochem       Date:  1998-11       Impact factor: 5.372

7.  Tau glycation is involved in aggregation of the protein but not in the formation of filaments.

Authors:  M D Ledesma; M Pérez; C Colaco; J Avila
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  1998-11       Impact factor: 1.770

8.  Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's disease.

Authors:  G Münch; A M Cunningham; P Riederer; E Braak
Journal:  Brain Res       Date:  1998-06-15       Impact factor: 3.252

Review 9.  Advanced glycation end products in neurodegeneration: more than early markers of oxidative stress?

Authors:  G Münch; M Gerlach; J Sian; A Wong; P Riederer
Journal:  Ann Neurol       Date:  1998-09       Impact factor: 10.422

Review 10.  Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors.

Authors:  P J Thornalley
Journal:  Chem Biol Interact       Date:  1998-04-24       Impact factor: 5.192

View more
  88 in total

1.  Neuroprotective Effects of Apocynin and Galantamine During the Chronic Administration of Scopolamine in an Alzheimer's Disease Model.

Authors:  Eliezer Joseph; Daniel Miguel Ángel Villalobos-Acosta; Mónica Adriana Torres-Ramos; Eunice Dalet Farfán-García; Modesto Gómez-López; Ángel Miliar-García; Manuel Jonathan Fragoso-Vázquez; Iohanan Daniel García-Marín; José Correa-Basurto; Martha Cecilia Rosales-Hernández
Journal:  J Mol Neurosci       Date:  2019-11-25       Impact factor: 3.444

Review 2.  Brain metabolic dysfunction at the core of Alzheimer's disease.

Authors:  Suzanne M de la Monte; Ming Tong
Journal:  Biochem Pharmacol       Date:  2013-12-28       Impact factor: 5.858

Review 3.  Oxidation as an important factor of protein damage: Implications for Maillard reaction.

Authors:  L Trnkova; J Drsata; I Bousova
Journal:  J Biosci       Date:  2015-06       Impact factor: 1.826

4.  Subcutaneous liraglutide ameliorates methylglyoxal-induced Alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation and glycogen synthase kinase-3β.

Authors:  Liqin Qi; Zhou Chen; Yanping Wang; Xiaoying Liu; Xiaohong Liu; Linfang Ke; Zhongjie Zheng; Xiaowei Lin; Yu Zhou; Lijuan Wu; Libin Liu
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

5.  The phosphodiesterase 5 inhibitor, KJH-1002, reverses a mouse model of amnesia by activating a cGMP/cAMP response element binding protein pathway and decreasing oxidative damage.

Authors:  Lijun Zhang; Jae Hong Seo; Huan Li; Ghilsoo Nam; Hyun Ok Yang
Journal:  Br J Pharmacol       Date:  2018-07-10       Impact factor: 8.739

Review 6.  Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors.

Authors:  Irene Bolea; Alejandro Gella; Mercedes Unzeta
Journal:  J Neural Transm (Vienna)       Date:  2012-12-13       Impact factor: 3.575

7.  Pretreatment of chemically-synthesized Aβ42 affects its biological activity in yeast.

Authors:  Afsaneh Porzoor; Joanne M Caine; Ian G Macreadie
Journal:  Prion       Date:  2014       Impact factor: 3.931

Review 8.  Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract Against AD and Other Neurological Disorders.

Authors:  Sandeep Kumar Singh; Saurabh Srivastav; Rudolph J Castellani; Germán Plascencia-Villa; George Perry
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

Review 9.  Molecular basis of etiological implications in Alzheimer's disease: focus on neuroinflammation.

Authors:  Rituraj Niranjan
Journal:  Mol Neurobiol       Date:  2013-02-19       Impact factor: 5.590

Review 10.  Ginkgo biloba extract in Alzheimer's disease: from action mechanisms to medical practice.

Authors:  Chun Shi; Jun Liu; Fengming Wu; David T Yew
Journal:  Int J Mol Sci       Date:  2010-01-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.